El-Sadawy M, Ragab H, el-Toukhy H, el-Mor Ael-L, Mangoud AM, Eissa MH, Afefy AF, el-Shorbagy E, Ibrahem IA, RAD001 Mahrous S, Abdel-Monem A, Sabee EI, Ismail A, Morsy TA, Etewa S, Nor Edin E, Mostafa Y, Abouel-Magd Y, Hassan MI, Lakouz K, Abdel-Aziz K, el-Hady G, Saber M: Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol 2004, 34 (Suppl 1) : 367–384.PubMed 11. Deuffic-Burban S, Mohamed 7-Cl-O-Nec1 MK, Larouze B, arrat F, Valleron AJ: Expected increase in hepatitis C-related mortality in
Egypt due to pre-2000 infections. J Hepatol 2006, 44: 455–461.CrossRefPubMed 12. Ahn J, Chung KS, Kim DU, Won M, Kim L, Kim KS, Nam M, Choi SJ, Kim HC, Yoon M, Chae SK, Hoe KL: Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J Biochem Mol Biol 2004, 37: 741–748.PubMed 13. Zekri
AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA: Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease DZNeP clinical trial progression. World Journal of Gastroenterology 2005, 11: 6624–6630.PubMed 14. Zekri AR, Haleem HA, Esmat GE, Bahnassy AA, El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS: Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepatol 2007, 14: 468–477.CrossRef 15. Chen J, Zheng XH, Tang XP: [A comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis]. Hunan Yi Ke Da Xue Xue Bao 2001, 26: 173–174.PubMed 16. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O, Antonaci S: Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 2000, 12: 811–814.CrossRefPubMed
17. Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, Daniele B, Curley SA: Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999, 6: 178–185.CrossRefPubMed 18. Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT: Biomedicines to reduce inflammation but not viral load in chronic HCV: what’s the sense? Trends Biotechnol 2004, 22: 517–523.CrossRefPubMed 19. Koulentaki M, Notas G, Petinaki E, Valatas V, Mouzas IA, Castanas E, Kouroumalis EA: Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Niclosamide Med 2004, 15: 35–38.CrossRefPubMed 20. Choi J, Ou JHJ: Mechanisms of liver injury: III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006, 290: G847-G851.CrossRefPubMed 21. Schwabe RF, Brenner DA: Mechanisms of liver injury: I.TNF-a- induced liver injury: role of IKK, JNK, ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006, 290: G583-G589.CrossRefPubMed 22. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M: Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B.